The increasing threat of antibiotic resistance in Africa, coupled with limited access to advanced antibiotics and high rates of bacterial infections, poses a serious public health challenge. Bacteriophages, viruses that target and destroy bacteria, present a promising alternative or complementary therapy to traditional antibiotics. Phage therapy leverages its unique ability to target specific bacterial strains without affecting the host's beneficial microbiota. It is an effective tool against multi-drug-resistant infections, particularly in resource-limited settings. This paper explores the potential of phage therapy in Africa, highlighting its advantages, such as specificity, minimal side effects, and cost-effectiveness, alongside its capability to tackle biofilm-associated and antibiotic-resistant infections. It reviews current research and collaborations, including case studies from Nigeria, Benin, and South Africa, that demonstrate the efficacy of phage therapy against pathogens like Staphylococcus aureus and Klebsiella pneumoniae. Furthermore, it discusses the challenges to implementation, such as regulatory hurdles, public scepticism, and infrastructure limitations, while emphasising the importance of developing local production and awareness campaigns. The paper concludes by recommending the integration of phage therapy into Africa’s healthcare strategies to address AMR. Through strategic partnerships, education, and regulatory frameworks, phage therapy could become a transformative solution, particularly for neglected diseases and infections common in low-resource settings. As Africa seeks innovative approaches to its growing AMR crisis, phage therapy stands out as a viable and adaptable option.